PAVmed Inc. is a medical device company. Its diversified pipeline of products address unmet clinical needs, which consists of CarpX (TM) to treat carpal tunnel syndrome; NextFlo(TM) and NextCath(TM) a disposable infusion pump; PortIO(TM) and NextCath interventional radiology and Caldus (TM) tissue ablation and cardiovascular intervention. PAVmed Inc. is headquartered in New York City.
| Revenue (Most Recent Fiscal Year) | $2.99M |
| Net Income (Most Recent Fiscal Year) | $39.79M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.28 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.83 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 3289.61% |
| Net Margin (Trailing 12 Months) | 3711.54% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -42.29% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.37 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 18.08 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.74 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.14 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.99 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.71 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 17.09M |
| Free Float | 15.85M |
| Market Capitalization | $10.52M |
| Average Volume (Last 20 Days) | 0.21M |
| Beta (Past 60 Months) | 1.11 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 19.93% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |